Galena Biopharma Inc (NASDAQ:GALE) on Mar. 3 announced the launch of Galena Patient Services (GPS), a full-service support program designed to enhance patient access to commercial products offered by the Company. Currently, Galena markets Abstral(R) (fentanyl) Sublingual Tablets for the treatment of breakthrough cancer pain. Galena Biopharma Inc (NASDAQ:GALE) stock opened at $3.33 in last session, and closed at $3.36, while the day range of stock is $3.20 – $3.45. The stock showed a negative weekly performance of -14.94%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares dropped 1.96% to $3.51. The company on Mar. 4 closed its previously announced underwritten public offering of 21,810,900 shares of the Company’s common stock, including 2,844,900 shares of common stock issued pursuant to the underwriter’s exercise of its overallotment option, at the public offering price of $2.90 per share. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock opened at $3.59, in last session and closed at $3.40, by losing -3.13%. The 52 week range of the stock is $0.49 – $3.95. Company’s market capitalization is $770.39 million.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has been trading with ups and downs since the past few days, after the company announced better-than-expected results and its plans to partner for its flagship drug Iclusig. Last week, the pharma company, which has been continuously involved to rebuild its brand for Iclusig, cheered the Wall Street by posting earnings per share of ($0.40) and revenue of $8.3 million. Both the numbers are higher than the expected ($0.47) earnings per share and $6.31 million revenue. One of the major takeaway during the earnings call is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s CEO Harvey Berger’s indication for potential partnership in Japan for Iclusig, as the formal announcement is expected to come soon. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock decreased -2.87% and finished the last session at $8.13. The EPS of the stock remained -1.49. Company’s market capitalization is $1.51 billion.
Just six weeks of Gilead Sciences Inc. (NASDAQ:GILD)’ hotly anticipated combination pill of ledipasvir and Sovaldi (sofosbuvir), given with or without GS-9669 or GS-9451, cured 95 to 100 percent of people with genotype 1 of hepatitis C virus (HCV) in a small pilot study, MedPage reports. Findings from the SYNERGY study were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened the session at $81.21, and closed the session at $79.58. The 52 week range of the stock remained $43.78 – $84.88 and the day range was $77.81 – $81.35.
Leave a Reply